XML 70 R59.htm IDEA: XBRL DOCUMENT
v3.19.1

Subsequent Events (Details Narrative) - Subsequent Event [Member] - USD ($) $ in Thousands | Feb. 18, 2019 | Feb. 08, 2019 | Jan. 23, 2019
--- | --- | --- | ---
Eyemax [Member] | Sean Brynjelsen [Member] |  |  |
Ownership interest percentage | 33.00% |  |
Licensing and Supply Agreement [Member] | Upon Execution of the Agreement [Member] |  |  |
Payment of license |  |  | $ 350
Licensing and Supply Agreement [Member] | Upon Successful Bioequivalence Study [Member] |  |  |
Payment of license |  |  | 350
Licensing and Supply Agreement [Member] | Upon NDA Acceptance [Member] |  |  |
Payment of license |  |  | 325
Licensing and Supply Agreement [Member] | Upon NDA Approval [Member] |  |  |
Payment of license |  |  | 325
Licensing and Supply Agreement [Member] | Upon Issuance of Patent [Member] |  |  |
Payment of license |  |  | 650
Licensing and Supply Agreement [Member] | Product Sales [Member] |  |  |
Payment of license |  |  | 500
Licensing and Supply Agreement [Member] | Maximum [Member] | Calendar Year [Member] |  |  |
Payment of license |  |  | $ 10,000
Exclusive Licensing and Supply Agreement - 202 [Member] |  |  |
Percentage for additional profit for commercial sale of product |  | 50.00% |
Exclusive Licensing and Supply Agreement - 202 [Member] | Upon FDA Approval [Member] |  |  |
Payment of license |  | $ 750 |
Exclusive Licensing and Supply Agreement - 203 [Member] |  |  |
Percentage for additional profit for commercial sale of product |  | 50.00% |
Exclusive Licensing and Supply Agreement - 203 [Member] | Upon FDA Approval [Member] |  |  |
Payment of license |  | $ 750 |
Amended and Restated Agreement [Member] | Maximum [Member] |  |  |
Royalties | $ 2,000 |  |
Liqmeds Worldwide Limited ("LMW") [Member] |  |  |
Percentage for product profit from commercial sales |  |  | 35.00%
Agreement term |  |  | 10 years
Liqmeds Worldwide Limited ("LMW") [Member] | Licensing and Supply Agreement [Member] | Maximum [Member] |  |  |
Payment of license |  |  | $ 2,500
Sintetica SA [Member] | Exclusive Licensing and Supply Agreement - 202 [Member] |  |  |
Payment of license |  | $ 2,000 |
Percentage for marketing fees |  | 5.00% |
Proceeds from license received |  | $ 500 |
Percentage for additional profit for commercial sale of product |  | 50.00% |
Agreement term for commercial sale of product |  | 10 years |
Sintetica SA [Member] | Exclusive Licensing and Supply Agreement - 203 [Member] |  |  |
Payment of license |  | $ 1,000 |
Percentage for marketing fees |  | 5.00% |
Proceeds from license received |  | $ 500 |
Percentage for additional profit for commercial sale of product |  | 50.00% |
Agreement term for commercial sale of product |  | 10 years |
Eyemax [Member] | Amended and Restated Agreement [Member] |  |  |
Description for milestone payment | Pursuant to the Amended Agreement, the Company remain obligated to pay Eyemax two milestones: (i) one milestone payment for $250,000 upon regulatory approval in the territory by the FDA of the first single agent product and (ii) one milestone payment for $500,000 following the first commercial sale of the first single agent product in the territory. |  |
Eyemax [Member] | Amended and Restated Agreement [Member] | One Milestone [Member] |  |  |
Payment for milestone | $ 250 |  |
Eyemax [Member] | Amended and Restated Agreement [Member] | Two Milestone [Member] |  |  |
Payment for milestone | 500 |  |
Bausch Health Ireland Limited [Member] | Asset Purchase Agreement [Member] |  |  |
Payment for milestone | 500 |  |
Bausch Health Ireland Limited [Member] | Asset Purchase Agreement [Member] | Commercial Milestone [Member] |  |  |
Payment for milestone | $ 2,500 |  |

X
- Definition The agreement is for an initial term. + References No definition available. + Details
Name: | ETON_AgreementTerm
Namespace Prefix: | ETON_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Agreement term for commercial sale of product. + References No definition available. + Details
Name: | ETON_AgreementTermForCommercialSaleOfProduct
Namespace Prefix: | ETON_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Description for milestone payment. + References No definition available. + Details
Name: | ETON_DescriptionForMilestonePayment
Namespace Prefix: | ETON_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Payment for milestone. + References No definition available. + Details
Name: | ETON_PaymentForMilestone
Namespace Prefix: | ETON_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage for marketing fees. + References No definition available. + Details
Name: | ETON_PercentageForMarketingFees
Namespace Prefix: | ETON_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage for product profit from commercial sales. + References No definition available. + Details
Name: | ETON_PercentageForProductProfitFromCommercialSales
Namespace Prefix: | ETON_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.15(a)) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.15(5)) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 + Details
Name: | us-gaap_AccruedRoyaltiesCurrentAndNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 + Details
Name: | us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Cash received from licensees for license fees during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585 + Details
Name: | us-gaap_ProceedsFromLicenseFeesReceived
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Percentage of subsidiary's or equity investee's stock owned by parent company before stock transaction. + References No definition available. + Details
Name: | us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=ETON_EyemaxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TitleOfIndividualAxis=ETON_SeanBrynjelsenMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ETON_LicensingAndSupplyAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementScenarioAxis=ETON_UponExecutionAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementScenarioAxis=ETON_UponSuccessfulBioequivalenceStudyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementScenarioAxis=ETON_UponNDAAcceptanceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementScenarioAxis=ETON_UponNDApprovalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementScenarioAxis=ETON_UponIssuanceOfPatentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementScenarioAxis=ETON_ProductSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementScenarioAxis=ETON_CalendarYearMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ETON_ExclusiveLicensingAndSupplyAgreementTwoHundredTwoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementScenarioAxis=ETON_UponFDAApprovalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ETON_ExclusiveLicensingAndSupplyAgreementTwoHundredThreeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ETON_AmendedAndRestatedAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=ETON_LiqmedsWorldwideLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=ETON_SinteticaSAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=ETON_EyemaxLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementScenarioAxis=ETON_OneMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementScenarioAxis=ETON_TwoMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=ETON_BauschHealthIrelandLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ETON_AssetPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementScenarioAxis=ETON_CommercialMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |